Lifecore Biomedical, Inc. (LFCR)
(Delayed Data from NSDQ)
$5.91 USD
-0.15 (-2.48%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $5.91 0.00 (0.00%) 7:58 PM ET
5-Strong Sell of 5 5
D Value B Growth D Momentum C VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
LFCR 5.91 -0.15(-2.48%)
Will LFCR be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for LFCR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LFCR
Lifecore (LFCR) Down 30% on Ending Strategic Review With No Deal
Strength Seen in Lifecore Biomedical (LFCR): Can Its 16.0% Jump Turn into More Strength?
LFCR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Vanda Pharmaceuticals (VNDA) Reports Break-Even Earnings for Q3
Will Lifecore Biomedical (LFCR) Report Negative Q1 Earnings? What You Should Know
Lifecore Biomedical (LFCR) Reports Q4 Loss, Tops Revenue Estimates
Other News for LFCR
Lifecore Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Graham & Doddsville Spring 2024 Newsletter From Columbia Business School
Lifecore Biomedical Completes Incremental Liquidity Initiatives
Lifecore Biomedical Asset Transfer for Creditor Settlement
Lifecore Biomedical Changes Executive Incentives to Stock Awards